Alcon Ophthalmology Company was founded with William Kona as the first president. The company began to produce professional ophthalmic drugs. Alexander and Kona prescribe during the day and prepare sterile vitamins for injection and oral drugs at night with filters and pressure cookers. The two far-sighted founders also opened a drive-in window to facilitate people to get medicine quickly according to prescriptions.
1950 In the late 1950s, Alcon Company introduced two kinds of ophthalmic drugs to the market for the first time-eye drops for treating minor eye infections and zinc Flynn for treating jealous itching.
1953 Bob Alexander invented the bucket. Plastic drop bottle and applied for a patent. This kind of packaging is now the standard packaging for eye care products.
1959 opened its first foreign branch in Canada and took the first step of her international operation.
1962 began to implement the patient assistance project, providing free medical assistance to low-income glaucoma patients and funding medical assistance projects worldwide.
1969 Alcon surgical products department was established with 7 employees.
The sales of 197 1 reached $3 1 10,000, and it was listed on the new york Stock Exchange.
1972 Ed Schollmaier, who has been working in Alcon since 1958, has been the president. During his tenure, Alcon's sales increased from $36 million to $2 billion in 1997, ranking first in the field of ophthalmic products in the world.
1978 Swiss food giant Nestle buys Alcon. The acquisition injected sufficient funds for Alcon to expand its production and business on a global scale and accelerated the internationalization of the company.
1979 began to establish a cooperative relationship with orbis to provide eye care services and training for medical professionals in poor areas around the world.
1982 William C. Connor R&D Center was established, and its world-leading research achievements in ophthalmic diseases were applied to the field of treatment.
1988 acquired Sharpoint Company and its manufacturing plant in Sinking Springs, Pennsylvania, and enriched the surgical product line by adding ophthalmic cutting instruments.
1989 acquired Coopervision surgical products department, merged with its own business at that time, and successfully built Alcon into the world's leading ophthalmic surgical products company.
1990 Irving technology center (ITC) was established in California, USA, and now it has become the most advanced research and development center of ophthalmic surgical instruments in the world.
1994 Acrysof & amp； Reg FDA's approval of intraocular lens marks the first successful research and development of special materials for intraocular lens. Today, Acrysof &；; Reg series intraocular lens has become the most widely used implantable intraocular lens in the world.
1997 Introduction to Patanol &; Reg eye drops have become the first choice for the treatment of allergic conjunctivitis.
1997 Acrysof & amp； Mr Tim Sear, who has been in charge of international business development for many years, is the third president and CEO of reg.
In 2000, Summit Autonomous Company and Grieshaber Company were acquired, thus entering the field of excimer laser refractive treatment and expanding the instrument product line of retinal surgery.
In 2000, Opti-Free &；; Reg express & ampreg
200 1 listed its first prostaglandin Travatan &: reg; Eye drops are used to reduce intraocular pressure in glaucoma patients.
In 2002, he re-entered the new york Stock Exchange and completed the listing of 25% of the shares. The value of the shares increased 40 times compared with that when he left 1978.
Several flagship products were launched in 2003, including Sytane &；; reg； Vigmos & eye drops; reg； ciprodex &； Suspension ear drops for the treatment of middle ear and external ear infections; Reg, and Acrysof & can filter ultraviolet and blue light; Reg natural intraocular lens.
Cary Rayment was appointed as the fourth president and CEO of Alcon in 2004. He joined Alcon with the merger of 1989 Cooper Vision Company.
acrysof &； RegReSTOR & ampreg intraocular lens went on the market all over the world, and soon became the global market leader of multifocal intraocular lens.
In 2006, Travatan Z&; Reg eye drops, and Acrysof &；; Reg toric intraocular lens has made a breakthrough in the treatment of glaucoma and cataract.
In 2007, PATADAY went on the market, which is the first eye drop used once a day in the world to treat eye itching related to eye allergy. , so as to further strengthen the ability to treat ocular allergic diseases.
In 2007, Wavelight AG was acquired through regulatory liquidation, further enriching the product portfolio in the field of refractive surgery.
In 2008, the first nasal product Patanase &; reg。 acrysof &； regCACHé？ . There are also IQ restorers &; Reg+3.0 D intraocular lens. Continue to expand acrysof &；; Reg artificial crystal series.
In 2008, Novartis bought about 25% shares of Alcon from Nestle, becoming the second largest shareholder of the company. And after the start of 20 10, the remaining 52% of Alcon shares of Nestle Holdings can be purchased first.
Acrysof &；, Alcon's main brand in 2009; Reg series intraocular lenses have been implanted with more than 40 million worldwide.
In 2009, Alcon USA was awarded 1 1 as one of the "Best Companies to Work for" by Fortune magazine.
2009 1984 Kevin Buehler, who joined Alcon's sales team, was appointed as the fifth president and CEO of Alcon.
In 20 10, Novartis and Alcon signed an agreement to complete the acquisition of 129 billion US dollars, and Alcon will be merged into Novartis and become Novartis shares and cash appreciation (CVA).